Manganese Enhanced Magnetic Resonance Imaging (MRI) in Ischaemic and Takotsubo Cardiomyopathy.

使用磁共振成像（MRI）扫描心脏可以详细评估其结构和功能。核磁共振成像可以通过在扫描过程中注入静脉的对比“染料”来提供有关心脏的更详细信息。这可以突出心脏内的异常区域。目前的对比染料有助于识别心脏内的疤痕。最近的研究使用一种含有锰的新型造影剂用于患有心脏动脉病变（缺血性心脏病）和影响心肌的心脏疾病（心肌病）的患者。这表明在缺血性心脏病和各种心肌病患者中染料摄取异常。它也显示出优于传统对比的优势；首先，它可以更准确地测量疤痕的数量，其次，它可以量化疤痕。心力衰竭是指心肌功能减弱，泵血功能下降。它是由各种情况引起的，包括不同的心脏肌肉疾病和影响心脏动脉的疾病。心力衰竭是一种全球性流行病，影响着全世界至少2600万人。尽管在治疗和预防方面取得了重大进展，但死亡率和发病率仍然很高，生活质量也很差。心力衰竭给医疗保健系统带来直接和间接成本，并对全球健康产生重大影响。我们计划进一步测试这种含锰染料，因为我们相信它将更好地了解可逆性心脏病。我们的研究将在女王医学研究所（QMRI）进行，该研究所位于爱丁堡皇家医院，由Trisha Singh博士领导。这是一项临床研究，将使用这种新型造影剂扫描三组患者；1)心脏动脉阻塞引起的心脏病发作（ii）心脏病引起的血液供需不匹配（心绞痛）（iii）继发于应激反应的心脏病（takotsubo）。我们将扫描健康志愿者进行比较。我们相信这种新药物有潜力更好地测量心脏疾病，提高我们确定心脏病病因的能力，帮助监测疾病的长期发展，并指导个体患者的未来治疗。这有可能改变临床实践，并对患者护理产生影响。

Scanning the heart using magnetic resonance imaging (MRI) enables detailed assessment of its structure and function. MRI can give more detailed information about the heart by using a contrast 'dye' that is injected into a vein during the scan. This can highlight abnormal areas within the heart. Current contrast dyes help identify scarring within the heart. Recent studies using a new contrast dye containing manganese has been used in patients with diseased heart arteries (ischemic heart disease) and cardiac conditions affecting the heart muscle (cardiomyopathy). This has shown abnormal uptake of the dye in patients with ischemic heart disease and various cardiomyopathies. It has also shown advantages over traditional contrast; firstly, it can measure the amount of scar more accurately and secondly it can quantify scar.Heart failure is a condition in which the heart muscle is weakened and pumping function is reduced. It is caused by various conditions including different heart muscle diseases and those affecting the heart arteries. Heart failure is a global pandemic affecting at least 26 million people worldwide. Despite the significant advances in therapies and prevention, mortality and morbidity are still high and quality of life poor. Heart failure imposes both direct and indirect costs to healthcare systems and has a significant impact on global health. We plan to further test this manganese containing dye as we believe it will provide better understanding into reversible cardiac conditions. Our study will be conducted in the Queen's Medical Research Institute (QMRI) at the Royal Infirmary Edinburgh led by Dr Trisha Singh. This is a clinical study which will involve using this new contrast agent to scan three patient groups; i) heart attacks by a blocked heart artery (ii) heart disease caused mismatch in blood supply and demand (angina) (iii) heart disease secondary to a stress response (takotsubo). We will scan healthy volunteers for comparison. We believe this new agent has potential to better measure disease in the heart, improve our ability to establish the cause of heart disease and help monitor the disease over time as well as guide future treatment for individual patients. This has the potential to change clinical practice and make an impact on patient care.